Interaction between natural killer cells and regulatory T cells: Perspectives for immunotherapy

Cellular and Molecular Immunology

Volumn 10, Issue 3, 2013, Pages 222-229

  Pedroza Pacheco, Isabela ^a   Madrigal, Alejandro ^a   Saudemont, Aurore ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

differentiation; effector functions; natural killer cells; regulatory T cells

Indexed keywords

CD14 ANTIGEN; CD209 ANTIGEN; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; HLA G ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 7; LENALIDOMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX86; NATURAL KILLER CELL RECEPTOR NKG2D; POMALIDOMIDE; SMAD4 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR PU 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CELL DEGENERATION; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL SURGERY; CYTOKINE PRODUCTION; GASTROINTESTINAL STROMAL TUMOR; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LEUKEMIA CELL; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NIDATION; NONHUMAN; PLACENTA DEVELOPMENT; PREGNANCY; PROSTATE CANCER; RECEPTOR UPREGULATION; REGULATORY T LYMPHOCYTE; REVIEW; T CELL DEPLETION; TUMOR REJECTION;

ANIMALS; AUTOIMMUNE DISEASES; CELL COMMUNICATION; FEMALE; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MODELS, IMMUNOLOGICAL; PREGNANCY; T-LYMPHOCYTES, REGULATORY;

EID: 84877616897     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2013.2     Document Type: Review

References (79)

1. Ljunggren HG, Karre K. In search of the 'missing self':MHCmolecules and NK cell recognition. Immunol Today 1990; 11: 237-244.
2. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9: 503-510.
3. Orentas RJ, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: Back to the future. Semin Cancer Biol 2006; 16: 137-149.
4. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3: 253-257.
5. Garin MI, Chu CC, Golshayan D, Cernuda-Morollon E, Wait R, Lechler RI. Galectin-1: A key effector of regulation mediated by CD41CD251 T cells. Blood 2007; 109: 2058-2065.
6. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A. CD251 CD41 T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 2001; 166: 3008-3018.
7. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-569.
8. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010; 11: 1093-1101.
9. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD41CD251Foxp31 regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD41 T cells. Nat Immunol 2007; 8: 1353-1362.
10. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004; 21: 589-601.
11. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD41CD251 regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194: 629-644.
12. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R et al. Expression of ectonucleotidase CD39 by Foxp31 Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110: 1225-1232.
13. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N et al. Immunologic self-tolerance maintained by CD251CD41 regulatory T cells constitutively expressing cytotoxic T lymphocyteassociated antigen 4. J Exp Med 2000; 192: 303-310.
14. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-1101.
15. Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 2008; 180: 5916-5926.
16. Sarris M, Andersen KG, Randow F, Mayr L, Betz AG. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008; 28: 402-413.
17. Thornton AM, Shevach EM. Suppressor effector function of CD41CD251 immunoregulatory T cells is antigen nonspecific. J Immunol 2000; 164: 183-190.
18. Trzonkowski P, Szmit E, Mysliwska J, Dobyszuk A, Mysliwski A. CD41CD251 T regulatory cells inhibit cytotoxic activity of T CD81 and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 2004; 112: 258-267.
19. Lim HW, Hillsamer P, Banham AH, Kim CH. Cutting edge: Direct suppression of B cells by CD41 CD251 regulatory T cells. J Immunol 2005; 175: 4180-4183.
20. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4: 1206-1212.
21. Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C et al. CD41CD251 regulatory T cells suppress mast cell degranulation and allergic responses through OX40- OX40L interaction. Immunity 2008; 29: 771-781.
22. Hua J, Liang S, Ma X, Webb TJ, Potter JP, Li Z. The interaction between regulatory T cells and NKT cells in the liver: A CD1d bridge links innate and adaptive immunity. PLoS One 2011; 6: E27038.
23. King A, Burrows T, Verma S, Hiby S, Loke YW. Human uterine lymphocytes. Hum Reprod Update 1998; 4: 480-485.
24. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunology 2002; 2: 656-663.
25. Sasaki Y, Sakai M, Miyazaki S, Higuma S, Shiozaki A, Saito S. Decidual and peripheral blood CD41CD251 regulatory T cells in early pregnancy subjects and spontaneous abortion cases. Mol Hum Reprod 2004; 10: 347-353.
26. Hsu P, Santner-Nanan B, Dahlstrom JE, Fadia M, Chandra A, Peek M et al. Altered decidual DC-SIGN1 antigen-presenting cells and impaired regulatory T-cell induction in preeclampsia. Am J Pathol 2012; 181: 2149-2160.
27. Vacca P, Cantoni C, Vitale M, Prato C, Canegallo F, Fenoglio D et al. Crosstalk between decidual NK and CD141 myelomonocytic cells results in induction of Tregs and immunosuppression. Proc Natl Acad Sci U S A 2010; 107: 11918-11941.
28. Keskin DB, Allan DS, Rybalov B, Andzelm MM, Stern JN, Kopcow HD et al. TGFbeta promotes conversion of CD161 peripheral blood NK cells into CD162 NK cells with similarities to decidual NK cells. Proc Natl Acad Sci U S A 2007; 104: 3378-3383.
29. Liu R, Van Kaer L, La Cava A, Price M, Campagnolo DI, CollinsMet al. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J Immunol 2006; 176: 5247-5254.
30. Piao WH, Jee YH, Liu RL, Coons SW, Kala M, Collins M et al. IL-21 modulates CD41 CD251 regulatory T-cell homeostasis in experimental autoimmune encephalomyelitis. Scand J Immunol 2008; 67: 37-46.
31. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, ChaputNet al. CD41CD251 regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med2005; 202: 1075-1085.
32. Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003; 171: 6891-6899.
33. Wu JD. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004; 114: 560-568.
34. Betts G, Jones E, Junaid S, El-Shanawany T, Scurr M, Mizen P et al. Suppression of tumour-specific CD41 T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 2012; 61: 1163-1171.
35. Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 2008; 129: 428-437.
36. Moo-Young TA, Larson JW, Belt BA, Tan MC, Hawkins WG, Eberlein TJ et al. Tumor-derived TGF-beta mediates conversion of CD41Foxp31 regulatory T cells in a murine model of pancreas cancer. J Immunother 2009; 32: 12-21.
37. Ralainirina N, Poli A, Michel T, Poos L, Andres E, Hentges F et al. Control of NK cell functions by CD41CD251 regulatory T cells. J Leukoc Biol 2007; 81: 144-153.
38. Zimmer J, Andres E, Hentges F. NK cells and Treg cells: A fascinating dance cheek to cheek. Eur J Immunol 2008; 38: 2942-2945.
39. Jonuleit H, Schmitt E. The regulatory T cell family: Distinct subsets and their interrelations. J Immunol 2003; 171: 6323-6327.
40. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, FautschSK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057.
41. Zhou H, Chen L, You Y, Zou L, Zou P. Foxp3-transduced polyclonal regulatory T cells suppress NK cell functions in a TGF-beta dependent manner. Autoimmunity 2010; 43: 299-307.
42. Bergmann C, Wild CA, Narwan M, Lotfi R, Lang S, Brandau S. Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells. Eur J Immunol 2011; 41: 3564-3573.
43. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F et al. Metronomic cyclophosphamide regimen selectively depletes CD41CD251 regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-648.
44. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008; 205: 825-839.
45. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206: 1717-1725.
46. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010; 107: 4275-4280.
47. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58: 1033-1045.
48. Davies FE. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
49. Shi FD, van Kaer L. Reciprocal regulation between natural killer cells and autoreactive T cells. Nat Rev Immunology 2006; 6: 751-760.
50. Brillard E, Pallandre JR, Chalmers D, Ryffel B, Radlovic A, Seilles E et al. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD41CD252 T lymphocytes. Exp Hematol 2007; 35: 416-425.
51. Roy S, Barnes PF, Garg A, Wu S, Cosman D, Vankayalapati R. NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J Immunol 2008; 180: 1729-1736.
52. Chin AI, Miyahira AK, Covarrubias A, Teague J, Guo B, Dempsey PW et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 2010; 70: 2595-2603.
53. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
54. Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007; 110: 4543-4551.
55. Beziat V, Nguyen S, Lapusan S, Hervier B, Dhedin N, Bories D et al. Fully functional NK cells after unrelated cord blood transplantation. Leukemia 2009; 23: 721-728.
56. Minamimura K, Gao W, Maki T. CD41 regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody. J Immunol 2006; 176: 4125-4132.
57. Bourgeois C, Stockinger B. CD251CD41 regulatory T cells and memory T cells prevent lymphopenia-induced proliferation of naive T cells in transient states of lymphopenia. J Immunol 2006; 177: 4558-4566.
58. Bayer A, Jones M, Chirinos J, de Armas L, Schreiber T, Malek T et al. Host CD41CD251 T cells can expand and comprise a major component of the Treg compartment after experimental HCT. Blood 2009; 113: 733-776.
59. Larsson J, Blank U, Helgadottir H, Bjornsson JM, Ehinger M, Goumans MJ et al. TGF-beta signaling-deficient hematopoietic stem cells have normal self-renewal and regenerative ability in vivo despite increased proliferative capacity in vitro. Blood 2003; 102: 3129-3135.
60. Larsson J, Karlsson S. The role of Smad signaling in hematopoiesis. Oncogene 2005; 24: 5676-5692.
61. Yamazaki S, Iwama A, Takayanagi S, Eto K, Ema H, Nakauchi H. TGFbeta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 2009; 113: 1250-1256.
62. Kale VP. Differential activation of MAPK signaling pathways by TGFbeta1 forms the molecular mechanism behind its dose-dependent bidirectional effects on hematopoiesis. Stem Cells Dev 2004; 13: 27-38.
63. Kale VP, Vaidya AA. Molecular mechanisms behind the dosedependent differential activation of MAPK pathways induced by transforming growth factor-beta1 in hematopoietic cells. Stem Cells Dev 2004; 13: 536-547.
64. Fujisaki J, Wu J, Carlson AL, Silberstein L, Putheti P, Larocca R et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature 2011; 474: 216-219.
65. Challen GA, Boles NC, Chambers SM, Goodell MA. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell 2010; 6: 265-278.
66. Marcoe JP, Lim JR, Schaubert KL, Fodil-Cornu N, Matka M, McCubbrey AL et al. TGF-beta is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy. Nat Immunol 2012; 13: 843-850.
67. Rorby E, Nifelt Hagerstrom M, Blank U, Karlsson G, Karlsson S. Human hematopoietic stem/progenitor cells overexpressing Smad4 exhibit impaired reconstitution potential in vivo. Blood 2012.
68. Martin-Fontecha A, Lord GM, Brady HJ. Transcriptional control of natural killer cell differentiation and function. Cell Mol Life Sci 2011; 68: 3495-3503.
69. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y. CD41CD251 T regulatory cells suppress NK cellmediated immunotherapy of cancer. J Immunol 2006; 176: 1582-1587.
70. Lundqvist A, Yokoyama H, Smith A, Berg M, Childs R. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 2009; 113: 6120-6127.
71. Sun X, Wu Y, Gao W, Enjyoji K, Csizmadia E, Muller CE et al. CD39/ENTPD1 expression by CD41Foxp31 regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 2010; 139: 1030-1040.
72. Romagnani C, Della Chiesa M, Kohler S, Moewes B, Radbruch A, Moretta L et al. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD41 T helper cells and CD41 CD25hi T regulatory cells. Eur J Immunol 2005; 35: 2452-2458.
73. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD251CD41 T cells: A common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211-5218.
74. Hallett WH, Ames E, Alvarez M, Barao I, Taylor PA, Blazar BR et al. Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses. Biol Blood Marrow Transplant 2008; 14: 1088-1099.
75. Hyka-Nouspikel N, Lucian L, Murphy E, McClanahan T, Phillips JH. DAP10 deficiency breaks the immune tolerance against transplantable syngeneic melanoma. J Immunol 2007; 179: 3763-3771.
76. Simon AK, Jones E, Richards H, Wright K, Betts G, Godkin A et al. Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. Eur J Immunol 2007; 37: 758-767.
77. Barao I, Hanash AM, Hallett W, Welniak LA, Sun K, Redelman D et al. Suppression of natural killer cell-mediated bone marrow cell rejection by CD41CD251 regulatory T cells. Proc Natl Acad Sci U S A 2006; 103: 5460-5465.
78. Kottke T, Galivo F, Wongthida P, Diaz RM, Thompson J, Jevremovic D et al. Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther 2008; 16: 1217-1226.
79. Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, CheraiM et al. CD41CD251 regulatory T cell depletion improves the graftversus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med 2010; 2: 41ra52.